Stewart W.  Strong net worth and biography

Stewart Strong Biography and Net Worth

Insider of Haemonetics
Stewart W. Strong joined Haemonetics in September 2019 as President, Global Hospital. He is responsible for overseeing the global Hospital business to drive market leadership and accelerate profitable growth. With more than 20 years of experience in Interventional cardiology and radiology, general and cardiac surgery and vascular access procedures, Mr. Strong has a robust background developing and leading high performance teams across multiple functions in the medical device space. Prior to joining Haemonetics, Mr. Strong was President and General Manager of the Interventional Business Unit for Teleflex Incorporated. While in this role, Mr. Strong helped to transform Teleflex into an established brand in the Interventional Cardiology space. Notably, Mr. Strong helped lead the successful $1 billion acquisition and integration of Vascular Solutions, Inc. in 2017 and the acquisition of Essential Medical in 2018. He previously held the role of Global Vice President and General Manager of Teleflex Cardiac Care and Vice President of Sales for their Vascular business unit. Mr. Strong joined Teleflex through the acquisition of Vidacare Corporation where he held the position of Vice President of Sales. Additionally, he has held leadership roles of increasing responsibility at AtriCure, Inc., Medtronic’s Heart Valve division and Johnson & Johnson’s Ethicon Endo-Surgery division. Mr. Strong is a graduate of the University of Connecticut.

What is Stewart W. Strong's net worth?

The estimated net worth of Stewart W. Strong is at least $1.43 million as of July 26th, 2024. Mr. Strong owns 18,196 shares of Haemonetics stock worth more than $1,433,299 as of December 19th. This net worth estimate does not reflect any other assets that Mr. Strong may own. Additionally, Mr. Strong receives a salary of $918,030.00 as Insider at Haemonetics. Learn More about Stewart W. Strong's net worth.

How old is Stewart W. Strong?

Mr. Strong is currently 57 years old. There are 5 older executives and no younger executives at Haemonetics. The oldest executive at Haemonetics is Mr. Josep Lluis Llorens, Executive Vice President of Global Manufacturing & Supply Chain, who is 62 years old. Learn More on Stewart W. Strong's age.

What is Stewart W. Strong's salary?

As the Insider of Haemonetics Co., Mr. Strong earns $918,030.00 per year. There are 4 executives that earn more than Mr. Strong. The highest earning executive at Haemonetics is Mr. Christopher A. Simon, CEO, President & Director, who commands a salary of $3,260,000.00 per year. Learn More on Stewart W. Strong's salary.

How do I contact Stewart W. Strong?

The corporate mailing address for Mr. Strong and other Haemonetics executives is 125 Summer Street, Boston MA, 02110. Haemonetics can also be reached via phone at (781) 848-7100 and via email at [email protected]. Learn More on Stewart W. Strong's contact information.

Has Stewart W. Strong been buying or selling shares of Haemonetics?

Stewart W. Strong has not been actively trading shares of Haemonetics during the last quarter. Most recently, Stewart W. Strong sold 4,312 shares of the business's stock in a transaction on Friday, July 26th. The shares were sold at an average price of $91.15, for a transaction totalling $393,038.80. Following the completion of the sale, the insider now directly owns 18,196 shares of the company's stock, valued at $1,658,565.40. Learn More on Stewart W. Strong's trading history.

Who are Haemonetics' active insiders?

Haemonetics' insider roster includes Michelle Basil (EVP), William Burke (CFO), Dan Goldstein (VP), Mark Kroll (Director), Anila Lingamneni (EVP), Josep Llorens (EVP), Richard Meelia (Director), Laurie Miller (SVP), Jacqueline Scanlan (SVP), Christopher Simon (CEO, President & Director), and Stewart Strong (Insider). Learn More on Haemonetics' active insiders.

Are insiders buying or selling shares of Haemonetics?

During the last twelve months, insiders at the medical instruments supplier sold shares 9 times. They sold a total of 33,828 shares worth more than $3,031,094.99. The most recent insider tranaction occured on July, 26th when insider Stewart W Strong sold 4,312 shares worth more than $393,038.80. Insiders at Haemonetics own 1.8% of the company. Learn More about insider trades at Haemonetics.

Information on this page was last updated on 7/26/2024.

Stewart W. Strong Insider Trading History at Haemonetics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/26/2024Sell4,312$91.15$393,038.8018,196View SEC Filing Icon  
5/29/2024Sell8,857$87.53$775,253.2118,196View SEC Filing Icon  
5/20/2024Sell686$95.11$65,245.4618,196View SEC Filing Icon  
5/16/2024Sell733$96.04$70,397.3215,608View SEC Filing Icon  
9/12/2023Sell228$90.65$20,668.2016,221View SEC Filing Icon  
10/24/2022Sell75$80.39$6,029.2515,681View SEC Filing Icon  
5/19/2022Sell1,084$59.10$64,064.4015,756View SEC Filing Icon  
10/25/2021Sell75$71.93$5,394.75View SEC Filing Icon  
See Full Table

Stewart W. Strong Buying and Selling Activity at Haemonetics

This chart shows Stewart W Strong's buying and selling at Haemonetics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Haemonetics Company Overview

Haemonetics logo
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $78.77
Low: $78.26
High: $82.27

50 Day Range

MA: $81.32
Low: $71.15
High: $93.38

2 Week Range

Now: $78.77
Low: $70.25
High: $97.97

Volume

518,622 shs

Average Volume

551,348 shs

Market Capitalization

$3.96 billion

P/E Ratio

32.68

Dividend Yield

N/A

Beta

0.38